Abstract

A device for evaluating the neurovirulence of a mumps virus, comprising: (I) a virus inoculation module, which is used for performing virus inoculation of a mumps virus to be evaluated on the lateral ventricle of a rat; (II) a processing module, which is used for performing vibration slicing on the fixed rat brain; (III) an imaging module, which is used for scanning and imaging the obtained rat brain slices; and (IV) an analysis module, which is used in the obtained imaging for calculating a neurovirulence index by using a formula I: the neurovirulence index=S1/S0×100 (formula I) according to the cross-sectional area S1 of a cavity formed by hydrocephalus in the longitudinal section of the rat brain and the total cross-sectional area S0 of the rat brain. Multiple results show that the results are stable, repeatability is high, and a wild strain may be distinguished from a vaccine strain. In addition, relative to a current monkey body neurovirulence model, animal cost and difficulty of operation are greatly reduced.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 1/28 - Preparing specimens for investigation
• G01N 1/36 - Embedding or analogous mounting of samples
• G01N 1/30 - StainingImpregnating

Abstract

Provided are an F-genotype mumps virus attenuated strain, a construction method therefor and an application thereof. The attenuated strain is a mumps virus with the accession number of CCTCC NO: V201950. Further provided are a vaccine composition containing the F-genotype mumps virus attenuated strain as an active ingredient and a preparation method thereof.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 39/165 - Mumps or measles virus

Abstract

Provided are a construction method and application of an F gene-replaced chimeric measles attenuated strain. Specifically, the present invention provides a chimeric measles virus attenuated strain, and the attenuated strain is a measles virus rMV/F(H1a) having a preservation number of CCTCCNO: V202101. The present invention further provides a vaccine composition containing the F gene-replaced chimeric measles attenuated strain or a derivative virus strain thereof as an active component and a preparation method of the vaccine composition.

IPC Classes  ?

• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 15/45 - Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
• C07K 14/12 - Mumps virusMeasles virus
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
• A61P 31/14 - Antivirals for RNA viruses
• C12R 1/93 - Animal viruses

Abstract

Provided are a construction method for an H-gene-replaced chimeric measles attenuated strain and an application thereof. The attenuated strain is a measles virus rMV/H(H1a) having an accession number of CCTCCNO: V202074. Further provided are a vaccine composition containing the H-gene-replaced chimeric measles attenuated strain or a derivative virus strain thereof as an active ingredient, and a preparation method therefor.

IPC Classes  ?

• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 15/45 - Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
• C07K 14/12 - Mumps virusMeasles virus
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
• A61P 31/14 - Antivirals for RNA viruses
• C12R 1/93 - Animal viruses

Abstract

Provided are an F-genotype mumps virus attenuated strain, a construction method therefor and an application thereof. The attenuated strain is a mumps virus QS-F-SH2 with the accession number of CCTCC NO: V201950. Further provided are a vaccine composition containing the F-genotype mumps virus attenuated strain as an active ingredient and a preparation method therefor.

IPC Classes  ?

• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• A61K 39/165 - Mumps or measles virus
• A61P 31/14 - Antivirals for RNA viruses
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/45 - Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
• C12R 1/93 - Animal viruses

Abstract

A device for evaluating the neurovirulence of a mumps virus, comprising: (I) a virus inoculation module, which is used for performing virus inoculation of a mumps virus to be evaluated on the lateral ventricle of a rat; (II) a processing module, which is used for performing vibration slicing on the fixed rat brain; (III) an imaging module, which is used for scanning and imaging the obtained mouse brain slices; and (IV) an analysis module, which is used in the obtained imaging for calculating a neurovirulence index by using a formula I: the neurovirulence index = S1/S0×100 (formula I) according to the cross-sectional area S1 of a cavity formed by hydrocephalus in the longitudinal section of the rat brain and the total cross-sectional area S0 of the rat brain. Multiple results show that the results are stable, repeatability is high, and a wild strain may be distinguished from a vaccine strain. In addition, relative to a current monkey body neurovirulence model, animal costs and difficulty of operation are greatly reduced.

IPC Classes  ?

• G01N 1/28 - Preparing specimens for investigation
• G01N 21/84 - Systems specially adapted for particular applications